Genor Biopharma updates on acquisition and reverse takeover progress

Genor Biopharma Holdings provided an update on its proposed very substantial acquisition and connected transaction, which includes a reverse takeover involving a new listing application. The company is actively addressing comments from regulators on the circular related to the transaction and needs additional time to compile financial information for the target company for the six months ended June 30, 2025. Genor Biopharma will apply to the Executive for an extension to the deadline for dispatch of the circular, according to Rule 8.2 of the Takeovers Code. Shareholders are cautioned that the merger is subject to the fulfillment or waiver of conditions precedent, approval of the new listing application, and the granting of a whitewash waiver.